• Something wrong with this record ?

Identification of disease phenotypes in acetylcholine receptor-antibody myasthenia gravis using proteomics-based consensus clustering

C. Nelke, CB. Schroeter, S. Barman, F. Stascheit, L. Masanneck, L. Theissen, N. Huntemann, S. Walli, D. Cengiz, V. Dobelmann, A. Vogelsang, M. Pawlitzki, S. Räuber, FF. Konen, T. Skripuletz, HP. Hartung, S. König, A. Roos, A. Meisel, SG. Meuth, T. Ruck

. 2024 ; 105 (-) : 105231. [pub] 20240702

Language English Country Netherlands

Document type Journal Article

BACKGROUND: The clinical heterogeneity of myasthenia gravis (MG), an autoimmune disease defined by antibodies (Ab) directed against the postsynaptic membrane, constitutes a challenge for patient stratification and treatment decision making. Novel strategies are needed to classify patients based on their biological phenotypes aiming to improve patient selection and treatment outcomes. METHODS: For this purpose, we assessed the serum proteome of a cohort of 140 patients with anti-acetylcholine receptor-Ab-positive MG and utilised consensus clustering as an unsupervised tool to assign patients to biological profiles. For in-depth analysis, we used immunogenomic sequencing to study the B cell repertoire of a subgroup of patients and an in vitro assay using primary human muscle cells to interrogate serum-induced complement formation. FINDINGS: This strategy identified four distinct patient phenotypes based on their proteomic patterns in their serum. Notably, one patient phenotype, here named PS3, was characterised by high disease severity and complement activation as defining features. Assessing a subgroup of patients, hyperexpanded antibody clones were present in the B cell repertoire of the PS3 group and effectively activated complement as compared to other patients. In line with their disease phenotype, PS3 patients were more likely to benefit from complement-inhibiting therapies. These findings were validated in a prospective cohort of 18 patients using a cell-based assay. INTERPRETATION: Collectively, this study suggests proteomics-based clustering as a gateway to assign patients to a biological signature likely to benefit from complement inhibition and provides a stratification strategy for clinical practice. FUNDING: CN and CBS were supported by the Forschungskommission of the Medical Faculty of the Heinrich Heine University Düsseldorf. CN was supported by the Else Kröner-Fresenius-Stiftung (EKEA.38). CBS was supported by the Deutsche Forschungsgemeinschaft (DFG-German Research Foundation) with a Walter Benjamin fellowship (project 539363086). The project was supported by the Ministry of Culture and Science of North Rhine-Westphalia (MODS, "Profilbildung 2020" [grant no. PROFILNRW-2020-107-A]).

References provided by Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc24019859
003      
CZ-PrNML
005      
20241024111051.0
007      
ta
008      
241015e20240702ne f 000 0|eng||
009      
AR
024    7_
$a 10.1016/j.ebiom.2024.105231 $2 doi
035    __
$a (PubMed)38959848
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a ne
100    1_
$a Nelke, Christopher $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
245    10
$a Identification of disease phenotypes in acetylcholine receptor-antibody myasthenia gravis using proteomics-based consensus clustering / $c C. Nelke, CB. Schroeter, S. Barman, F. Stascheit, L. Masanneck, L. Theissen, N. Huntemann, S. Walli, D. Cengiz, V. Dobelmann, A. Vogelsang, M. Pawlitzki, S. Räuber, FF. Konen, T. Skripuletz, HP. Hartung, S. König, A. Roos, A. Meisel, SG. Meuth, T. Ruck
520    9_
$a BACKGROUND: The clinical heterogeneity of myasthenia gravis (MG), an autoimmune disease defined by antibodies (Ab) directed against the postsynaptic membrane, constitutes a challenge for patient stratification and treatment decision making. Novel strategies are needed to classify patients based on their biological phenotypes aiming to improve patient selection and treatment outcomes. METHODS: For this purpose, we assessed the serum proteome of a cohort of 140 patients with anti-acetylcholine receptor-Ab-positive MG and utilised consensus clustering as an unsupervised tool to assign patients to biological profiles. For in-depth analysis, we used immunogenomic sequencing to study the B cell repertoire of a subgroup of patients and an in vitro assay using primary human muscle cells to interrogate serum-induced complement formation. FINDINGS: This strategy identified four distinct patient phenotypes based on their proteomic patterns in their serum. Notably, one patient phenotype, here named PS3, was characterised by high disease severity and complement activation as defining features. Assessing a subgroup of patients, hyperexpanded antibody clones were present in the B cell repertoire of the PS3 group and effectively activated complement as compared to other patients. In line with their disease phenotype, PS3 patients were more likely to benefit from complement-inhibiting therapies. These findings were validated in a prospective cohort of 18 patients using a cell-based assay. INTERPRETATION: Collectively, this study suggests proteomics-based clustering as a gateway to assign patients to a biological signature likely to benefit from complement inhibition and provides a stratification strategy for clinical practice. FUNDING: CN and CBS were supported by the Forschungskommission of the Medical Faculty of the Heinrich Heine University Düsseldorf. CN was supported by the Else Kröner-Fresenius-Stiftung (EKEA.38). CBS was supported by the Deutsche Forschungsgemeinschaft (DFG-German Research Foundation) with a Walter Benjamin fellowship (project 539363086). The project was supported by the Ministry of Culture and Science of North Rhine-Westphalia (MODS, "Profilbildung 2020" [grant no. PROFILNRW-2020-107-A]).
650    _2
$a lidé $7 D006801
650    12
$a myasthenia gravis $x krev $x diagnóza $x imunologie $x metabolismus $7 D009157
650    12
$a receptory cholinergní $x imunologie $x metabolismus $7 D011950
650    12
$a autoprotilátky $x krev $x imunologie $7 D001323
650    12
$a proteomika $x metody $7 D040901
650    12
$a fenotyp $7 D010641
650    _2
$a ženské pohlaví $7 D005260
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a lidé středního věku $7 D008875
650    _2
$a dospělí $7 D000328
650    _2
$a shluková analýza $7 D016000
650    _2
$a proteom $7 D020543
650    _2
$a senioři $7 D000368
650    _2
$a B-lymfocyty $x metabolismus $x imunologie $7 D001402
650    _2
$a aktivace komplementu $7 D003167
655    _2
$a časopisecké články $7 D016428
700    1_
$a Schroeter, Christina B $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
700    1_
$a Barman, Sumanta $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
700    1_
$a Stascheit, Frauke $u Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany
700    1_
$a Masanneck, Lars $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
700    1_
$a Theissen, Lukas $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
700    1_
$a Huntemann, Niklas $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
700    1_
$a Walli, Sara $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
700    1_
$a Cengiz, Derya $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
700    1_
$a Dobelmann, Vera $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
700    1_
$a Vogelsang, Anna $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
700    1_
$a Pawlitzki, Marc $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
700    1_
$a Räuber, Saskia $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
700    1_
$a Konen, Felix F $u Department of Neurology, Hannover Medical School, Hannover, Germany
700    1_
$a Skripuletz, Thomas $u Department of Neurology, Hannover Medical School, Hannover, Germany
700    1_
$a Hartung, Hans-Peter $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany; Brain and Mind Center, University of Sydney, Sydney NSW, Australia; Department of Neurology, Palacky University Olomouc, Olomouc, Czech Republic
700    1_
$a König, Simone $u Core Unit Proteomics, Interdisciplinary Center for Clinical Research, Medical Faculty, University of Münster, Münster, Germany
700    1_
$a Roos, Andreas $u Department of Neuropaediatrics, Neuromuscular Centre, Universitätsmedizin Essen, Essen, Germany
700    1_
$a Meisel, Andreas $u Department of Neurology, Charité - Universitätsmedizin Berlin, Berlin, Germany
700    1_
$a Meuth, Sven G $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany
700    1_
$a Ruck, Tobias $u Department of Neurology, Medical Faculty, Heinrich Heine University Duesseldorf, Duesseldorf, Germany. Electronic address: Tobias.Ruck@med.uni-duesseldorf.de
773    0_
$w MED00190061 $t EBioMedicine $x 2352-3964 $g Roč. 105 (20240702), s. 105231
856    41
$u https://pubmed.ncbi.nlm.nih.gov/38959848 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y - $z 0
990    __
$a 20241015 $b ABA008
991    __
$a 20241024111045 $b ABA008
999    __
$a ok $b bmc $g 2202208 $s 1231832
BAS    __
$a 3
BAS    __
$a PreBMC-MEDLINE
BMC    __
$a 2024 $b 105 $c - $d 105231 $e 20240702 $i 2352-3964 $m EBioMedicine $n EBioMedicine $x MED00190061
LZP    __
$a Pubmed-20241015

Find record

Citation metrics

Loading data ...

Archiving options

Loading data ...